Superior in vivo efficacy of afucosylated trastuzumab in the treatment of HER2-amplified breast cancer.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 20484044.
- Also identified by DOI 10.1158/0008-5472.CAN-09-3704.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The enhancement of immune effector functions has been proposed as a potential strategy for increasing the efficacy of therapeutic antibodies. Here, we show that removing fucose from trastuzumab (Herceptin) increased its binding to FcgammaRIIIa, enhanced antibody-dependent cell-mediated cytotoxicity, and more than doubled the median progression-free survival when compared with conventional trastuzumab in treating preclinical models of HER2-amplified breast cancer. Our results show that afucosylated trastuzumab has superior efficacy in treating in vivo models of HER2-amplified breast cancer and support the development of effector function-enhanced antibodies for solid tumor therapy.
Medical subject headings
- Antibodies, Monoclonal
- Breast Neoplasms
- Erb-b2 Receptor Tyrosine Kinases